Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT01783535
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- The Methodist Hospital Research Institute
- Registration Number
- NCT01736800
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Methodist Neurological Institute - Department of Neurosurgery, Houston, Texas, United States
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01690598
- Locations
- 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2016-03-04
- Target Recruit Count
- 13
- Registration Number
- NCT01683149
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 141
- Registration Number
- NCT01630018
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Seoul Metropolitan, Korea, Republic of
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 37
- Registration Number
- NCT01593228
- Locations
- 🇺🇸
Investigational Site Number 840025, Sioux City, Iowa, United States
🇺🇸Investigational Site Number 840030, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840043, Cleveland, Ohio, United States
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 179
- Registration Number
- NCT01500720
- Locations
- 🇷🇴
Investigational Site Number 642001, Craiova, Romania
🇬🇷Investigational Site Number 300005, Athens, Greece
🇺🇸Investigational Site Number 840006, Lebanon, New Hampshire, United States
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 164
- Registration Number
- NCT01497873
- Locations
- 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇰🇷Chungbuk University Hospital, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Center, Daegu, Korea, Republic of
Indirect Comparison Topotecan Cervical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01345279
Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 3
- Registration Number
- NCT01177501
- Locations
- 🇫🇷
Frédéric Selle, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.